Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of the Usefulness of Diagnostic Tests for Rheumatoid Arthritis

류마티스 관절염 진단을 위한 검사의 유용성 비교

  • Park, Chang-Eun (Deptartment Biomedical Laboratory Science, Namseoul University)
  • 박창은 (남서울대학교 임상병리학과)
  • Received : 2015.10.22
  • Accepted : 2015.11.02
  • Published : 2015.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which is mainly characterized by disease of joints affected with synovial hyperplasia, pathological immune response, and progressive destruction; all of which represent an important social health problem. These provide new insights in its pathogenesis of rheumatoid arthritis diagnosis and disease progression in molecular changes. This review focuses on new serological and immunological markers which seem to be useful in early diagnosis and prognosis of rheumatoid arthritis. Therefore, such tests are widely conducted for serological biomarkers and the developments with such immunological factors to identify patients who are at risk for disease progression. This evidence of the disease based on laboratory medicine could provide the best outcome for patients. Finally, data from recent studies will help to refine the ultimate usefulness of this novel approach for early diagnosis, treatment, and helping clinicians to optimize therapy by using this approach.

류마티스 관절염은 주로 관절의 활막 세포의 증식, 병리학적 면역 반응과 관절의 진행성 파괴를 특징으로 하는 만성 염증성 질환이다. 이 질환은 중요한 사회적 건강 문제로 대두된다. 이 논문을 통해 분자수준에서 변화와 류마티스 관절염의 진단 또는 질병의 진행에 대한 발병 기전을 새로운 관점에서 발병기전을 제공한다. 또한 조기 진단과 류마티스 관절염의 예후에 도움이 될 것으로 보인다. 새로운 혈청학적 및 면역학적 바이오마커에 초점을 맞추고 있다. 따라서 넓게 질병 진행의 위험 환자를 식별하는 혈청학적, 생체 면역학적 요인 등을 규명하고 적용시키는 것을 도출할 수 있다. 진단 검사 의학을 기반으로 하는 증거는 환자에게 최선의 결과를 제공할 수 있다. 마지막으로. 최근의 연구 데이터는 이 접근을 통해서 치료를 최적화하기 위해 조기 진단 및 치료에 도움이 되는 새로운 접근 방식으로 궁극적인 유용성을 정립하는데 도움이 될 것으로 사료된다.

Keywords

References

  1. Andersen T, Hvid M, Johansen C, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K, et al. Interleukin-23 in early disease development in rheumatoid arthritis. Scand J Rheumatol. 2015, 19:1-5.
  2. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum. 2001, 45:101-106. https://doi.org/10.1002/1529-0131(200102)45:1<101::AID-ANR90>3.0.CO;2-7
  3. Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB. Prognostic biomarkers in osteoarthritis. Current Opinion in Rheumatology. 2013, 25:136-144. https://doi.org/10.1097/BOR.0b013e32835a9381
  4. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996, 26:526-538. https://doi.org/10.1016/S0049-0172(96)80041-2
  5. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008, 118:3537-3545. https://doi.org/10.1172/JCI36389
  6. Castro-Santos P, Laborde CM, Diaz-Pena R. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers. Clin Exp Rheumatol. 2015, 33:279-286.
  7. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis. 2014, 5:e1102. https://doi.org/10.1038/cddis.2014.70
  8. Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol. 2015, 179:137-145. https://doi.org/10.1111/cei.12467
  9. Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis. 2015, 17:e1887.
  10. Cribbs A, Feldmann M, Oppermann U. Towards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implications. Ther Adv Musculoskelet Dis. 2015, 7:206-219. https://doi.org/10.1177/1759720X15598307
  11. Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013, 166:622-628. https://doi.org/10.1016/j.ahj.2013.07.010
  12. Dessein PH, Solomon A, Woodiwiss AJ, Norton GR, Tsang L, Gonzalez-Gay MA. Marked independent relationships between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis. Mediators Inflamm. 2013, 2013:510243.
  13. Gerlag DM, Norris JM, Tak PP. RA: from risk factors and pathogenesis to prevention: Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology. 2015, pii: kev347.
  14. Gibson DS, Bustard MJ, McGeough CM, Murray HA, Crockard MA, McDowell A, et al. Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Rev Mol Diagn. 2015, 15:219-234. https://doi.org/10.1586/14737159.2015.969244
  15. Goeb V, Jouen F, Gilbert D, Le Loet X, Tron F, Vittecoq O. Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine. 2009, 76:343-349. https://doi.org/10.1016/j.jbspin.2008.12.006
  16. Han BK, Olsen NJ, Bottaro A. The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin Arthritis Rheum. 2015, 15:199-207.
  17. Hayashi N, Kumagai S. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis. Rinsho Byori. 2010, 58:466-479.
  18. Jimenez SA, Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific noncoding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjogren's syndrome. Autoimmun Rev. 2013, 12:1046-1051. https://doi.org/10.1016/j.autrev.2013.04.004
  19. Kaneko Y, Kuwana M, Kameda H, Takeuchi T. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2011, 50(7):1268-1274. https://doi.org/10.1093/rheumatology/keq442
  20. Kim DA, Kim TY. Anti-microtubule organizing center with microtubule by autoimmune target test is also useful serological marker in rheumatoid arthritis evaluation. Rheumatol Int. 2013, 33:805-808. https://doi.org/10.1007/s00296-011-2228-9
  21. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005, 23:1-21. https://doi.org/10.1146/annurev.immunol.23.021704.115806
  22. Kitagawa T, Shibasaki K, Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol. 2012, 31:105-112. https://doi.org/10.1007/s10067-011-1789-z
  23. Koller MD. Targeted therapy in rheumatoid arthritis. Wien Med Wochenschr. 2006, 156:53-60. https://doi.org/10.1007/s10354-005-0245-6
  24. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol. 2005, 6:789-800. https://doi.org/10.1038/nrm1740
  25. Lapteva N, Ide K, Nieda M, Ando Y, Hatta-Ohashi Y, et al. Activation and suppression of reninangiotensin system in human dendritic cells. Biochem Biophys Res Commun. 2002, 296:194-200. https://doi.org/10.1016/S0006-291X(02)00855-0
  26. Lettieri Barbato D, Aquilano K, Baldelli S, Cannata SM, Bernardini S, Rotilio G, et al. Proline oxidase-adipose triglyceride lipase pathway restrains adipose cell death and tissue inflammation. Cell Death Differ. 2014, 21:113-123. https://doi.org/10.1038/cdd.2013.137
  27. Mariani A, Marsili M, Nozzi M, Faricelli R, Chiarelli F, Breda L. Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases. Clin Exp Rheumatol. 2015, 33:109-114.
  28. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011, 365:2205-2219. https://doi.org/10.1056/NEJMra1004965
  29. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and metaanalysis. Arch Cardiovasc Dis. 2010, 103:253-261. https://doi.org/10.1016/j.acvd.2010.03.007
  30. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008, 58:1284-1292. https://doi.org/10.1002/art.23429
  31. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009, 157:209-215. https://doi.org/10.1111/j.1365-2249.2009.03944.x
  32. Niimoto T, Nakasa T, Ishikawa M, Okuhara A, Izumi B, Deie M, et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord. 2010, 11:209. https://doi.org/10.1186/1471-2474-11-209
  33. Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 2008, 58:2686-2693. https://doi.org/10.1002/art.23758
  34. Nishino J, Tanaka S, Kadono Y, Matsui T, Komiya A, Nishimura K, et al. The usefulness of neutrophil CD64 expression in the diagnosis of local infection in patients with rheumatoid arthritis in daily practice. J Orthop Sci. 2010, 15:547-552. https://doi.org/10.1007/s00776-010-1498-5
  35. Oh JS, Park CB. Study on Seropositive Rate of Rheumatoid arthritis Test in the Medi-screeners. Korean J Clin Lab Sci. 1997, 29:35-42.
  36. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol. 2006, 35:169-174. https://doi.org/10.1080/03009740600718080
  37. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Cheek L, et al. Foot pain in rheumatoid arthritis prevalence, risk factors and management: an epidemiological study. Clin Rheumatol. 2010, 29:255-271. https://doi.org/10.1007/s10067-009-1312-y
  38. Park M, Pyun JC, Akter H, Nguyen BT, Kang MJ. Evaluation of a specific diagnostic marker for rheumatoid arthritis based on cyclic citrullinated peptide. J Pharm Biomed Anal. 2015, 115:107-113. https://doi.org/10.1016/j.jpba.2015.06.032
  39. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10:R101. https://doi.org/10.1186/ar2493
  40. Reyes-Castillo Z, Palafox-Sanchez CA, Parra-Rojas I, Martinez-Bonilla GE, Del Toro-Arreola S, Ramirez-Duenas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol. 2015, 182:119-131. https://doi.org/10.1111/cei.12677
  41. Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T, et al. Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol. 2012, 39:1517-1523. https://doi.org/10.3899/jrheum.111601
  42. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection. 1998, 26:274-276. https://doi.org/10.1007/BF02962246
  43. Segurado OG, Sasso EH. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2014, 32:S-29-34.
  44. Shi LL, Chen P, Xun YP, Yang WK, Yang CH, Chen GY, et al. Prohibitin as a novel autoantigen in rheumatoid arthritis. Cent Eur J Immunol. 2015, 40:78-82.
  45. Smith EP, Shanks K, Lipsky MM, DeTolla LJ, Keegan AD, Chapoval SP. Expression of neuroimmune semaphorins 4A and 4D and their receptors in the lung is enhanced by allergen and vascular endothelial growth factor. BMC Immunol. 2011, 12:30. https://doi.org/10.1186/1471-2172-12-30
  46. Smolen JS, Alehata D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol. 2012, 8:235-243. https://doi.org/10.1038/nrrheum.2012.23
  47. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with RA traditional risk factors versus markers of RA severity. Ann Rheum Dis. 2010, 69:1920-1925. https://doi.org/10.1136/ard.2009.122226
  48. Suzuki A, Yamamoto K. From genetics to functional insights into rheumatoid arthritis. Clin Exp Rheumatol. 2015, 33:40-43.
  49. Teixeira PC, Ferber P, Vuilleumier N, Cutler P. Biomarkers for cardiovascular risk assessment in autoimmune diseases. Proteomics Clin Appl. 2015, 9:48-57. https://doi.org/10.1002/prca.201400125
  50. Theiss AL, Jenkins AK, Okoro NI, Klapproth JM, Merlin D, Sitaraman SV. Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin a3 expression. Mol Biol Cell. 2009, 20:4412-4423. https://doi.org/10.1091/mbc.e09-05-0361
  51. Theiss AL, Sitaraman SV. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta. 2011, 1813:1137-1143. https://doi.org/10.1016/j.bbamcr.2011.01.033
  52. Traves PG, Pardo V, Pimentel-Santillana M, Gonzalez- Rodriguez A, Mojena M, Rico D, et al. Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge. Cell Death Dis. 2014, 5:e1125. https://doi.org/10.1038/cddis.2014.90
  53. Wang L, Song G, Zheng Y, Tan W, Pan J, Zhao Y, et al. Expression of Semaphorin 4A and its potential role in rheumatoid arthritis. Arthritis Res Ther. 2015, 17:227. https://doi.org/10.1186/s13075-015-0734-y
  54. Yang XK, Xu WD, Leng RX, Liang Y, Liu YY, Fang XY, et al. Therapeutic potential of IL-15 in rheumatoid arthritis. Hum Immunol. 2015, 15:478-484.
  55. Zhang WC, Wu H, Chen WX. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide 2 antibody and anti-cyclic citrullinated peptide 3 antibody in rheumatoid arthritis. Clin Chem Lab Med. 2014, 52(6):779-790.
  56. Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-${\alpha}$. Nat Med. 2012, 18:1077-1086. https://doi.org/10.1038/nm.2815
  57. Zordan P, Rigamonti E, Freudenberg K, Conti V, Azzoni E, Rovere-Querini P, et al. Macrophages commit postnatal endothelium-derived progenitors to angiogenesis and restrict endothelial to mesenchymal transition during muscle regeneration. Cell Death Dis. 2014, 5:e1031. https://doi.org/10.1038/cddis.2013.558